Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 May;69(5):924–930. doi: 10.1038/bjc.1994.179

Prostatic carcinoma: a multivariate analysis of prognostic factors.

A Berner 1, S Harvei 1, S Tretli 1, S D Fosså 1, J M Nesland 1
PMCID: PMC1968899  PMID: 7514029

Abstract

Tissue specimens from 150 patients with localised prostatic carcinomas and 116 patients with prostatic carcinomas with distant metastases were analysed for histological grade (WHO and Gleason) and immunoreactivity for prostate acid phosphatase (PAP), prostate-specific antigen (PSA), neurone-specific enolase (NSE), p53 protein, c-erbB-2 protein, cytokeratins (AE1/AE3) and vimentin. After stratification for the presence or absence of distant metastases, multivariate regression analysis revealed that WHO grading was the most powerful independent prognosticator, followed by age and prostate acid phosphatase expression. There was a trend towards reduced survival with decreasing prostate-specific antigen reactivity. The Gleason system showed poor prognostic ability. The analysis predicted reduced survival in the presence of extensive neurone-specific enolase reactivity, mostly because of one case of small-cell carcinoma.

Full text

PDF
924

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bazinet M., Hamdy S. M., Bégin L. R., Stephenson R. A., Fair W. R. Prognostic significance of antigenic heterogeneity, Gleason grade, and ploidy of lymph node metastases in patients with prostate cancer. Prostate. 1992;20(4):311–326. doi: 10.1002/pros.2990200406. [DOI] [PubMed] [Google Scholar]
  2. Berner A., Nesland J. M., Waehre H., Silde J., Fosså S. D. Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens. Br J Cancer. 1993 Aug;68(2):380–384. doi: 10.1038/bjc.1993.344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Blute M. L., Nativ O., Zincke H., Farrow G. M., Therneau T., Lieber M. M. Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy. J Urol. 1989 Nov;142(5):1262–1265. doi: 10.1016/s0022-5347(17)39051-1. [DOI] [PubMed] [Google Scholar]
  4. Cohen R. J., Glezerson G., Haffejee Z. Neuro-endocrine cells--a new prognostic parameter in prostate cancer. Br J Urol. 1991 Sep;68(3):258–262. doi: 10.1111/j.1464-410x.1991.tb15318.x. [DOI] [PubMed] [Google Scholar]
  5. Epstein J. I., Eggleston J. C. Immunohistochemical localization of prostate-specific acid phosphatase and prostate-specific antigen in stage A2 adenocarcinoma of the prostate: prognostic implications. Hum Pathol. 1984 Sep;15(9):853–859. doi: 10.1016/s0046-8177(84)80146-x. [DOI] [PubMed] [Google Scholar]
  6. Epstein J. I., Paull G., Eggleston J. C., Walsh P. C. Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup. J Urol. 1986 Oct;136(4):837–839. doi: 10.1016/s0022-5347(17)45097-x. [DOI] [PubMed] [Google Scholar]
  7. Epstein J. I., Pizov G., Walsh P. C. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer. 1993 Jun 1;71(11):3582–3593. doi: 10.1002/1097-0142(19930601)71:11<3582::aid-cncr2820711120>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  8. Feiner H. D., Gonzalez R. Carcinoma of the prostate with atypical immunohistological features. Clinical and histologic correlates. Am J Surg Pathol. 1986 Nov;10(11):765–770. doi: 10.1097/00000478-198611000-00003. [DOI] [PubMed] [Google Scholar]
  9. Gallee M. P., Ten Kate F. J., Mulder P. G., Blom J. H., van der Heul R. O. Histological grading of prostatic carcinoma in prostatectomy specimens. Comparison of prognostic accuracy of five grading systems. Br J Urol. 1990 Apr;65(4):368–375. doi: 10.1111/j.1464-410x.1990.tb14758.x. [DOI] [PubMed] [Google Scholar]
  10. Gullick W. J., Love S. B., Wright C., Barnes D. M., Gusterson B., Harris A. L., Altman D. G. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer. 1991 Mar;63(3):434–438. doi: 10.1038/bjc.1991.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hale R. J., Buckley C. H., Fox H., Williams J. Prognostic value of c-erbB-2 expression in uterine cervical carcinoma. J Clin Pathol. 1992 Jul;45(7):594–596. doi: 10.1136/jcp.45.7.594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hammond M. E., Sause W. T., Martz K. L., Pilepich M. V., Asbell S. O., Rubin P., Myers R. P., Farrow G. M. Correlation of prostate-specific acid phosphatase and prostate-specific antigen immunocytochemistry with survival in prostate carcinoma. Cancer. 1989 Feb 1;63(3):461–466. doi: 10.1002/1097-0142(19890201)63:3<461::aid-cncr2820630312>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  13. Hsu S. M., Raine L., Fanger H. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol. 1981 May;75(5):734–738. doi: 10.1093/ajcp/75.5.734. [DOI] [PubMed] [Google Scholar]
  14. Humphrey P. A., Walther P. J., Currin S. M., Vollmer R. T. Histologic grade, DNA ploidy, and intraglandular tumor extent as indicators of tumor progression of clinical stage B prostatic carcinoma. A direct comparison. Am J Surg Pathol. 1991 Dec;15(12):1165–1170. doi: 10.1097/00000478-199112000-00007. [DOI] [PubMed] [Google Scholar]
  15. Johansson J. E., Adami H. O., Andersson S. O., Bergström R., Krusemo U. B., Kraaz W. Natural history of localised prostatic cancer. A population-based study in 223 untreated patients. Lancet. 1989 Apr 15;1(8642):799–803. doi: 10.1016/s0140-6736(89)92269-1. [DOI] [PubMed] [Google Scholar]
  16. Kant A. K., Glover C., Horm J., Schatzkin A., Harris T. B. Does cancer survival differ for older patients? Cancer. 1992 Dec 1;70(11):2734–2740. doi: 10.1002/1097-0142(19921201)70:11<2734::aid-cncr2820701127>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  17. Leong A. S., Gilham P., Milios J. Cytokeratin and vimentin intermediate filament proteins in benign and neoplastic prostatic epithelium. Histopathology. 1988 Oct;13(4):435–442. doi: 10.1111/j.1365-2559.1988.tb02059.x. [DOI] [PubMed] [Google Scholar]
  18. Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453–456. doi: 10.1038/351453a0. [DOI] [PubMed] [Google Scholar]
  19. McCann A., Dervan P. A., Johnston P. A., Gullick W. J., Carney D. N. c-erbB-2 oncoprotein expression in primary human tumors. Cancer. 1990 Jan 1;65(1):88–92. doi: 10.1002/1097-0142(19900101)65:1<88::aid-cncr2820650119>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  20. Mellon K., Thompson S., Charlton R. G., Marsh C., Robinson M., Lane D. P., Harris A. L., Horne C. H., Neal D. E. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol. 1992 Feb;147(2):496–499. doi: 10.1016/s0022-5347(17)37287-7. [DOI] [PubMed] [Google Scholar]
  21. Murphy G. P., Natarajan N., Pontes J. E., Schmitz R. L., Smart C. R., Schmidt J. D., Mettlin C. The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol. 1982 May;127(5):928–934. doi: 10.1016/s0022-5347(17)54135-x. [DOI] [PubMed] [Google Scholar]
  22. Nagle R. B., Brawer M. K., Kittelson J., Clark V. Phenotypic relationships of prostatic intraepithelial neoplasia to invasive prostatic carcinoma. Am J Pathol. 1991 Jan;138(1):119–128. [PMC free article] [PubMed] [Google Scholar]
  23. O'Reilly S. M., Barnes D. M., Camplejohn R. S., Bartkova J., Gregory W. M., Richards M. A. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer. 1991 Mar;63(3):444–446. doi: 10.1038/bjc.1991.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Partin A. W., Steinberg G. D., Pitcock R. V., Wu L., Piantadosi S., Coffey D. S., Epstein J. I. Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. Cancer. 1992 Jul 1;70(1):161–168. doi: 10.1002/1097-0142(19920701)70:1<161::aid-cncr2820700126>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  25. Porter P. L., Gown A. M., Kramp S. G., Coltrera M. D. Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue. Am J Pathol. 1992 Jan;140(1):145–153. [PMC free article] [PubMed] [Google Scholar]
  26. Ro J. Y., Têtu B., Ayala A. G., Ordóez N. G. Small cell carcinoma of the prostate. II. Immunohistochemical and electron microscopic studies of 18 cases. Cancer. 1987 Mar 1;59(5):977–982. doi: 10.1002/1097-0142(19870301)59:5<977::aid-cncr2820590521>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  27. Sakai H., Shiraishi K., Minami Y., Yushita Y., Kanetake H., Saito Y. Immunohistochemical prostatic acid phosphatase level as a prognostic factor of prostatic carcinoma. Prostate. 1991;19(3):265–272. doi: 10.1002/pros.2990190307. [DOI] [PubMed] [Google Scholar]
  28. Schroeder F. H., Hop W. C., Blom J. H., Mostofi F. K. Grading of prostatic cancer: III. Multivariate analysis of prognostic parameters. Prostate. 1985;7(1):13–20. doi: 10.1002/pros.2990070103. [DOI] [PubMed] [Google Scholar]
  29. Sherwood E. R., Theyer G., Steiner G., Berg L. A., Kozlowski J. M., Lee C. Differential expression of specific cytokeratin polypeptides in the basal and luminal epithelia of the human prostate. Prostate. 1991;18(4):303–314. doi: 10.1002/pros.2990180404. [DOI] [PubMed] [Google Scholar]
  30. Smith J. A., Jr, Hernandez A. D., Wittwer C. J., Avent J. M., Greenwood J., Hammond E. H., Middleton R. G. Long-term follow-up after radical prostatectomy. Identification of prognostic variables. Urol Clin North Am. 1991 Aug;18(3):473–476. [PubMed] [Google Scholar]
  31. Stamey T. A., Yang N., Hay A. R., McNeal J. E., Freiha F. S., Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987 Oct 8;317(15):909–916. doi: 10.1056/NEJM198710083171501. [DOI] [PubMed] [Google Scholar]
  32. Têtu B., Ro J. Y., Ayala A. G., Johnson D. E., Logothetis C. J., Ordonez N. G. Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer. 1987 May 15;59(10):1803–1809. doi: 10.1002/1097-0142(19870515)59:10<1803::aid-cncr2820591019>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  33. Van Veldhuizen P. J., Sadasivan R., Garcia F., Austenfeld M. S., Stephens R. L. Mutant p53 expression in prostate carcinoma. Prostate. 1993;22(1):23–30. doi: 10.1002/pros.2990220104. [DOI] [PubMed] [Google Scholar]
  34. Visakorpi T., Kallioniemi O. P., Heikkinen A., Koivula T., Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst. 1992 Jun 3;84(11):883–887. doi: 10.1093/jnci/84.11.883. [DOI] [PubMed] [Google Scholar]
  35. Ware J. L., Maygarden S. J., Koontz W. W., Jr, Strom S. C. Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. Hum Pathol. 1991 Mar;22(3):254–258. doi: 10.1016/0046-8177(91)90159-m. [DOI] [PubMed] [Google Scholar]
  36. Whitmore W. F., Jr, Warner J. A., Thompson I. M., Jr Expectant management of localized prostatic cancer. Cancer. 1991 Feb 15;67(4):1091–1096. doi: 10.1002/1097-0142(19910215)67:4<1091::aid-cncr2820670437>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  37. Woodcock-Mitchell J., Eichner R., Nelson W. G., Sun T. T. Immunolocalization of keratin polypeptides in human epidermis using monoclonal antibodies. J Cell Biol. 1982 Nov;95(2 Pt 1):580–588. doi: 10.1083/jcb.95.2.580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. di Sant'Agnese P. A., de Mesy Jensen K. L. Neuroendocrine differentiation in prostatic carcinoma. Hum Pathol. 1987 Aug;18(8):849–856. doi: 10.1016/s0046-8177(87)80060-6. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES